Tonix Pharmaceuticals Holding Corp (TNXP)

[mick]

i just give outstanding data. $TNXP “More than 200 years of vaccine experience, beginning with Dr. Edward Jenner’s landmark discoveries with horsepox and cowpox vaccines, have shown that
T cell eliciting vaccines are particularly effective against viruses,” said Seth Lederman, M.D., President and CEO of Tonix.
“We believe that protective vaccines against the SARS-CoV-2 virus will be similar in that regard.
The data we plan to collect from recovered and asymptomatic COVID-19 volunteers will inform vaccine development on how to safely
provide to vaccine recipients the same immune responses that others got from recovering from actual CoV-2 infection.
If approved by the U.S. Food and Drug Administration (FDA) for use in healthy, non-pregnant adults without moderate or severe eczema,

TNX-1800 would feature single-dose immunity without the use of adjuvants, ease of manufacturing on readily available systems,
and glass-sparing distribution since we believe 100 doses of TNX-1800 could be packaged in a single vial.
Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed.”